Core Viewpoint - The issuance of an executive order by President Donald Trump to reschedule cannabis from Schedule I to Schedule III under the U.S. Controlled Substances Act is a significant development for the cannabis industry, enhancing operational economics and enabling expanded medical research [2][3]. Company Summary - LEEF Brands, Inc. is a leading multi-state operator in the cannabis industry, focusing on extraction, manufacturing, and cultivation, with operations in California and New York [6]. - The rescheduling of cannabis to Schedule III will eliminate the 280E tax burden, improving cash flow and allowing LEEF to reinvest in its workforce, facilities, and long-term growth [3]. - The company operates state-of-the-art extraction and cultivation facilities and believes that the removal of 280E will strengthen balance sheets across the sector, providing more growth capital for expansion [3][4]. Industry Summary - The rescheduling of cannabis is expected to improve access to capital across the cannabis industry, potentially attracting institutional investors and broadening the pool of available lenders [4]. - Improved regulatory clarity may lower the overall cost of capital, creating opportunities for companies to fund growth and scale operations more efficiently [4]. - LEEF is also monitoring developments related to hemp-derived cannabinoids and potential Medicare coverage for certain CBD products, with a pilot program expected as early as 2026 [4].

Core Viewpoint - U.S. President Donald Trump's decision to relax marijuana regulations may alleviate some challenges for cannabis companies, but it is unlikely to improve their access to capital from major banks [1] Group 1 - The relaxation of marijuana regulations could reduce operational burdens for cannabis companies [1] - Experts suggest that despite regulatory changes, access to capital from big banks will remain restricted for the cannabis industry [1]

Core Viewpoint - The Cannabist Company Holdings Inc. has entered into an agreement to sell its Virginia subsidiary, Green Leaf Medical of Virginia, LLC, for a total consideration of $130 million, following a go-shop process that identified a superior acquisition proposal [1][8]. Transaction Details - The sale involves the purchase of all equity interests of Green Leaf Virginia for $130 million, with $117.5 million payable in cash at closing and $12.5 million held in escrow for post-closing adjustments [3]. - The transaction is subject to certain closing conditions, including regulatory approvals, and is expected to close early in 2026 [4]. Financial Implications - The company plans to use a portion of the net proceeds from the transaction to redeem its Senior Secured Notes [5]. Strategic Review - A special committee of independent directors has been formed to explore strategic alternatives, including asset sales and mergers, in light of ongoing operational and financial challenges [9]. Background Information - The Cannabist Company, formerly known as Columbia Care, operates 77 facilities across 12 U.S. jurisdictions, including 61 dispensaries and 16 cultivation and manufacturing facilities [11].

Group 1 - Tilray Brands closed at $12.34, down 4.2%, and has fallen 94% since its IPO in 2018, with trading volume at 66.7 million shares, 514% above its three-month average [1] - The cannabis industry reacted to President Trump's executive order reclassifying marijuana, with the S&P 500 gaining 0.79% and the Nasdaq Composite rising 1.38%, while peers Canopy Growth and Cronos Group fell by 12% and 2% respectively [2] - Following the reclassification of cannabis from Schedule I to Schedule III, Tilray's stock initially rose but ended the day down 4%, indicating a potential "buy the rumor, sell the news" scenario [3][4] Group 2 - The reclassification may not have met investor expectations for broader recreational use, which could have positively impacted Tilray [4] - Despite the recent news, Tilray remains a risky investment as it is barely profitable on an EBITDA basis, although the reclassification should provide some support for the company [4]

impact. Let's bring in Kim Rivery of True Leave. She was at the signing this afternoon.Kim, great to have you with us. >> Thanks so much for having me. How much does this actually help your company and how much of it is symbolic.>> Well, I mean, first of all, the fact that President Trump had the first uh meaningful cannabis policy reform action since cannabis was scheduled back in the 70s. I would say it's a pretty it's a pretty monumental day. Um like you said in the intro, it does two things.It first of ...

Core Viewpoint - President Trump signed an executive order to reclassify marijuana from Schedule I to Schedule III, facilitating medical research and potentially impacting the cannabis industry positively [1][2][3] Group 1: Reclassification Impact - The reclassification allows for easier federally approved research on marijuana, which could lead to new medical applications and market opportunities [5] - Cannabis businesses may gain access to federal tax deductions, unlocking significant tax savings and research opportunities [4] Group 2: Medical Research and Economic Effects - The order emphasizes the potential of marijuana as a substitute for opioid painkillers, highlighting its legitimate medical applications [3] - The reclassification is expected to have immediate economic effects, creating new investment opportunities while also presenting risks [4]

Industry Overview - Cannabis industry stocks have experienced a rally this week, driven by fluctuating news that significantly impacts stock performance [1] Market Sentiment - The market sentiment around cannabis stocks is characterized by volatility, with gains often followed by declines, reflecting the unpredictable nature of news affecting these stocks [1]

Core Insights - The rescheduling of cannabis from Schedule I to Schedule III under the Controlled Substances Act marks a significant policy shift, recognizing its medical use and paving the way for a more regulated national cannabis market [1][2] Group 1: Federal Rescheduling Impact - The Schedule III status will alleviate federal policy barriers, enhance access to banking, and allow companies to deduct ordinary business expenses previously restricted under 280E, thereby freeing up capital for patient care, product innovation, and market expansion [2] - This rescheduling follows a recent federal clarification regarding hemp-derived intoxicants, which is expected to reduce unlicensed competition and alleviate pricing pressures, particularly in key states like Florida and Texas [3] Group 2: Company Commitment and Operations - FLUENT Corp. is dedicated to operational excellence in cultivation, production, distribution, and retail, producing a diverse range of cannabis products under various brands [4] - The company operates in multiple states, including Florida, New York, Pennsylvania, and Texas, employing 700 staff across 8 cultivation and manufacturing facilities and 37 retail locations [4]

Core Points - Cannabis has been rescheduled from a Class 1 to a Class 3 substance under the Controlled Substances Act, marking a significant reform in its legal status [1][2] - The new law will enable the IRS to collaborate with legal cannabis businesses, providing them with tax breaks and incentives [1] - The bill aims to enhance cannabis research and redefine hemp to ensure full-spectrum CBD is accessible to patients [2] Industry Impact - The rescheduling is seen as a win for corporate cannabis, but it may pose challenges for smaller craft cannabis operators, potentially disrupting the coexistence of mom-and-pop brands in the industry [5] - Initial reactions in the marijuana stock market were muted, but there is potential for increased trading activity as investors fully digest the news [5] - The cannabis sector may experience a rise in stock prices as the week closes, depending on investor sentiment [5]

Core Viewpoint - The potential rescheduling of marijuana to a Schedule III drug under the Controlled Substances Act could significantly transform the cannabis industry, particularly benefiting Village Farms International, Inc. and its CBDistillery business [1][2]. Group 1: Company Advocacy and Legal Strategy - Village Farms commended President Trump's Executive Order aimed at rescheduling marijuana, which could modernize U.S. cannabis policy and align it with international standards [1][2]. - The company's legal strategy during DEA proceedings was pivotal in advocating for the rescheduling of cannabis, showcasing its commitment to reform and collaboration with policymakers [2]. Group 2: Production and Market Position - Village Farms operates one of the largest cannabis cultivation facilities globally, with 2.2 million square feet of greenhouse assets and 950 acres of farmland in Texas, positioning it well to meet increasing demand for medical cannabis products [2][4]. - The company has a strong foundation in controlled environment agriculture and is leveraging its expertise to expand into cannabinoid-based therapeutic products while maintaining its produce assets [3]. Group 3: International and Domestic Expansion - Internationally, Village Farms is targeting growth opportunities in legal cannabis markets, exporting medical cannabis to countries like Germany, the UK, and Australia, and expanding its export business [5]. - In the U.S., the company plans to enter the THC market using its Texas-based greenhouse assets, which include 2.2 million square feet of existing capacity and additional land for future expansion [6].